Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2019 | 1 |
2020 | 2 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models.
Breast Cancer Res Treat. 2020 Apr;180(2):359-368. doi: 10.1007/s10549-020-05558-w. Epub 2020 Feb 6.
Breast Cancer Res Treat. 2020.
PMID: 32030569
Free PMC article.
Metabolism and Pharmacokinetic Study of the Boron-Containing Prodrug of Belinostat (ZL277), a Pan HDAC Inhibitor with Enhanced Bioavailability.
Zhang C, Guo S, Zhong Q, Zhang Q, Hossain A, Zheng S, Wang G.
Zhang C, et al.
Pharmaceuticals (Basel). 2019 Dec 8;12(4):180. doi: 10.3390/ph12040180.
Pharmaceuticals (Basel). 2019.
PMID: 31817969
Free PMC article.
Item in Clipboard
Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents.
Wang G.
Wang G.
Transl Cancer Res. 2020 Aug;9(8):4464-4468. doi: 10.21037/tcr-20-2166.
Transl Cancer Res. 2020.
PMID: 32968620
Free PMC article.
No abstract available.
Item in Clipboard
Cite
Cite